NICE rejects groundbreaking Alzheimer’s drugs: What it means for the UK
In a move that has triggered disappointment across the [...]
A new era in Alzheimer’s diagnosis: What the FDA’s first approved blood test means for the UK
On 16 May 2025, the U.S. Food and Drug [...]
Dementia trends: a declining incidence but a growing burden
Dementia is one of the biggest healthcare challenges of the [...]
What will it take to transform Alzheimer’s with the new wave of medicines?
The first wave of effective Disease Modifying Therapies (DMT) [...]
